These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34656974)

  • 1. Correspondence on "Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure" by Joshi
    Yalta K; Ozkan U; Yalta T
    Heart; 2021 Dec; 107(23):1922. PubMed ID: 34656974
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to: Correspondence on "Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure" by Yalta
    Joshi SS; Singh T; Singh J; Newby DE
    Heart; 2021 Dec; 107(23):1922-1923. PubMed ID: 34656972
    [No Abstract]   [Full Text] [Related]  

  • 3. Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart Failure.
    Patoulias D; Papadopoulos C; Doumas M
    J Stroke Cerebrovasc Dis; 2022 Mar; 31(3):106257. PubMed ID: 34953683
    [No Abstract]   [Full Text] [Related]  

  • 4. The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure: A Call to Overcome Clinical Inertia.
    Khan MS; Butler J; Greene SJ
    Circ Heart Fail; 2020 Dec; 13(12):e008030. PubMed ID: 33161728
    [No Abstract]   [Full Text] [Related]  

  • 5. Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF.
    Bocchi EA; Biolo A; Moura LZ; Figueiredo Neto JA; Montenegro CEL; Albuquerque DC
    Arq Bras Cardiol; 2021 Feb; 116(2):355-358. PubMed ID: 33656089
    [No Abstract]   [Full Text] [Related]  

  • 6. Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations.
    Butler J; Anker SD; Filippatos G; Usman MS; Ferreira JP; Zannad F; Packer M
    Eur Heart J; 2021 Dec; 42(48):4887-4890. PubMed ID: 34718518
    [No Abstract]   [Full Text] [Related]  

  • 7. Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
    Tsampasian V; Elghazaly H; Chattopadhyay R; Ali O; Corballis N; Chousou PA; Clark A; Garg P; Vassiliou VS
    Eur J Prev Cardiol; 2022 May; 29(6):e227-e229. PubMed ID: 34850881
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys.
    Lioudaki E; Joslin JR; Trachanatzi E; Androulakis E
    Rev Cardiovasc Med; 2022 Mar; 23(3):82. PubMed ID: 35345249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction.
    Liang B; Liang Y; Gu N
    BMC Cardiovasc Disord; 2022 Jun; 22(1):261. PubMed ID: 35689186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and uric acid: More good news!
    Katsiki N; Rizzo M; Mikhailidis DP
    J Diabetes Complications; 2023 Jul; 37(7):108510. PubMed ID: 37235924
    [No Abstract]   [Full Text] [Related]  

  • 11. Sodium-Glucose Co-Transporter-2 Inhibitor Therapy During Anthracycline Treatment: Is There a Role for Cardioprotection?
    Khouri MG; Greene SJ
    JACC Heart Fail; 2022 Aug; 10(8):568-570. PubMed ID: 35902160
    [No Abstract]   [Full Text] [Related]  

  • 12. Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials.
    Liang B; Gu N
    Int J Med Sci; 2022; 19(7):1118-1121. PubMed ID: 35919809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond the myocardium: Sodium-glucose co-transporter-2 inhibitors in heart failure.
    Chilton RJ
    Diabetes Obes Metab; 2021 May; 23(5):1215-1218. PubMed ID: 33464709
    [No Abstract]   [Full Text] [Related]  

  • 14. Sodium-glucose co-transporter 2 inhibitors in heart failure.
    Rosano GMC; Vitale C; Savarese G
    Eur Heart J Cardiovasc Pharmacother; 2021 May; 7(3):e9-e10. PubMed ID: 33576409
    [No Abstract]   [Full Text] [Related]  

  • 15. Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.
    Nana M; Morgan H; Bondugulapati LNR
    Heart Fail Rev; 2021 Jul; 26(4):953-960. PubMed ID: 32020487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose co-transporter 2 inhibitors and acute heart failure.
    Groenewegen A; Rutten FH
    Eur J Heart Fail; 2020 Apr; 22(4):723-725. PubMed ID: 32072715
    [No Abstract]   [Full Text] [Related]  

  • 17. The sodium-glucose co-transporter 2 inhibitor dapagliflozin improves prognosis in systolic heart failure independent of the obesity paradox.
    Carbone S; daSilva-deAbreu A; Lavie CJ
    Eur J Heart Fail; 2021 Oct; 23(10):1673-1676. PubMed ID: 34427026
    [No Abstract]   [Full Text] [Related]  

  • 18. The far-reaching beneficial effects of sodium-glucose co-transporter 2 inhibitors in heart failure.
    Crea F
    Eur Heart J; 2022 Aug; 43(31):2907-2910. PubMed ID: 35963617
    [No Abstract]   [Full Text] [Related]  

  • 19. Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors?
    Berezin AE; Berezin AA
    Future Cardiol; 2021 May; 17(3):497-506. PubMed ID: 33615880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors.
    Karagkounis D
    Drug Ther Bull; 2023 Jul; 61(7):103-107. PubMed ID: 37380347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.